C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies

Lupus

Volumn 21, Issue 14, 2012, Pages 1497-1505

  Carrera Marin A L ^a,b   Romay Penabad, Z ^a   Papalardo, E ^a   Reyes Maldonado, E ^b   Garcia Latorre E ^b   Vargas, G ^c   Shilagard, T ^c   Pierangeli, S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Anticardiolipin antibodies; antiphospholipid syndrome; complement activation; lupus anticoagulant; thrombosis

Indexed keywords

ANTIBODY; BETA 2 GLYCOPROTEIN ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C6; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHOLIPID ANTIBODY; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; C6 MOUSE; CAROTID ARTERY; CONTROLLED STUDY; FEMALE; HOMOGENATE; HUMAN; KNOCKOUT MOUSE; MOUSE; MOUSE STRAIN; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOPHILIA; THROMBOSIS; UPREGULATION; WILD TYPE;

ADULT; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CAROTID ARTERIES; COMPLEMENT C6; FEMALE; FEMORAL VEIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; MIDDLE AGED; THROMBOPHILIA; THROMBOPLASTIN; THROMBOSIS; UP-REGULATION;

EID: 84869382834     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312458839     Document Type: Article

References (51)

1. Harris EN. Syndrome of the black swan. Br J Rheumatol. 1987 ; 26: 324-326
2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4: 295-306
3. Pierangeli SS, Colden-Stanfield M, Liu X, et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation. 1999 ; 99: 1997-2002
4. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA. 1991 ; 88: 3069-3073
5. Chamley LW, Duncalf AM, Mitchell MD, Johnson PM. Action of anticardiolipin and antibodies to β2glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet. 1998 ; 352: 1037-1038
6. Espinola RG, Liu X, Colden-Stanfield M, Hall J, et al. E-selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost. 2002 ; 1: 843-848
7. Vega-Ostertag ME, Casper K, Swerlick R, et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum. 2005 ; 52: 1545-1554
8. Del Papa N, Guidali L, Sala A, et al. Endothelial cells as target for antiphospholipid antibodies - Human polyclonal and monoclonal anti-β2. glycoprotein I antibodies react in vitro with endothelial cells through adherent β2. glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997 ; 40: 551-561
9. Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995 ; 96: 2211-2219
10. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res. 2001 ; 88: 245-250
11. Cuadrado MJ, López-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome - A pivotal role for monocyte tissue factor expression. Arthritis Rheum. 1997 ; 40: 834-841
12. Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in antiphospholipid-mediated platelet activation. Arthritis Rheum. 2004 ; 50: 2911-2919
13. Forastiero RR, Martinuzzo ME, De Larranaga GF. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprous related antiphospholipid antibodies. Lupus. 2005 ; 14: 129-136
14. Williams FM, Parmar K, Hughes GR, Hunt BJ. Systemic endothelial cell markers in antiphospholipid syndrome. Thromb Haemost. 2000 ; 84: 742-746
15. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits upregulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost. 2004 ; 2: 1558-1563
16. Montiel-Manzano G, Romay-Penabad Z, Papalardo de Martinez E, et al. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Ann N Y Acad Sci. 2007 ; 1108: 540-553
17. Dunoyer-Geindre S, De Moerloose P, Galve-de Rochemonteiz B, et al. NFκB is an essential intermediate in the activation of endothelial cells by anti- β2glycoprotein I antibodies. Thromb Haemost. 2002 ; 88: 851-857
18. Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-β2glycoprotein I antibodies. Int Immunol. 2004 ; 16: 1632-1641
19. Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood. 2009 ; 114: 3074-3083
20. Pierangeli SS, Vega-Ostertag ME, Raschi E, et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis. 2007 ; 66: 1327-1333
21. Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT, et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood. 2011 ; 117: 1408-1414
22. Shin ML, Ros HG, Nicolescu FI, et al. Membrane attack by complement assembly and biology of terminal complement complexes. Biomembranes. 1996 ; 4: 123-129
23. Hansch GM, Seitz M, Betz M. Effect of late complement components C5b-9 on human monocytes: release of prostanoids, oxygen radicals and of a factor inducing cell proliferation. Int Arch Allergy Immunol. 1987 ; 82: 317-320
24. Ikeda K, Nagasawa K, Horiuchi T, et al. C5a induces tissue factor activity on endothelial cells. Thromb Haemost. 1997 ; 77: 394-398
25. Saadi S, Holznecht RA, Patte CP, et al. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med. 1995 ; 182: 1807-1814
26. Pan ZK. Anaphylotoxins C5a and C3a induce nuclear factor kappa B activation in human peripheral blood monocytes. Biochim Biophys Acta. 1998 ; 1443: 90-98
27. Chiou W, Tsai H, Yang L, Tsai W. C5a differentially stimulates the ERK1/2 and p38 MAPK phosphorylation through independent signaling pathways to induced chemotactic migration in RAW264.7 macrophages. Int Immunopharmacol. 2004 ; 4: 1329-1341
28. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, Adler S, et al. CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol. 1998 ; 9: 590-597
29. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis. 2002 ; 61: ii46 - ii50
30. Pierangeli SS, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis and Rheumatism. 2005 ; 52: 2120-2124
31. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002 ; 195: 211-220
32. Romay-Penabad Z, Liu XX, Montiel-Manzano G, et al. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann N Y Acad Sci. 2007 ; 1108: 554-566
33. Redecha P, Tilley R, Tencati M, et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood. 2007 ; 110: 2423-2431
34. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004 ; 10: 1222-1226
35. Bradford MM. A refined and sensitive method for the Quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 ; 72: 248-254
36. Pierangeli SS, Harris EN. A protocol for determination of anticardiolipin antibodies by ELISA. Nat Protoc. 2008 ; 3: 840-848
37. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005 ; 106: 2340-2346
38. Pierangeli SS, Liu XW, Barker JH, et al. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost. 1995 ; 74: 1361-1367
39. Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood. 2005 ; 105: 192-198
40. Ferrara DE, Weiss D, Carnell PH, et al. Quantitative 3D fluorescence technique for the analysis of en face preparations of arterial walls using quantum dot nanocrystals and two-photon excitation laser scanning microscopy. Am J Physiol Regulatory Integrative Comp Physiol. 2006 ; 290: 114-123
41. Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science. 1998 ; 281: 2016-2018
42. Gao X, Nie S. Molecular profiling of single cells and tissue specimens with quantum dots. Trends in Biotech. 2003 ; 21: 371-373
43. Chan WC, Maxwell DJ, Gao X, et al. Luminescent quantum dots for multiplexed biological detection and imaging. Curr Op Biotech. 2002 ; 13: 40-46
44. Carbone J, Oerra M, Rodriguez-Mahou M, et al. Immunological abnormalities. in primary APS evolving into SLE: 6 years follow-up in women with repeated. pregnancy loss. Lupus. 1999 ; 8: 274-278
45. Tincani A, Gilburd B, Abu-Shakra M, et al. Immunization of naïve Balb/c mice with human b2glycoprotein I breaks tolerance to the murine molecule. Arthritis Rheum. 2002 ; 46: 1399-1404
46. Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis. 2009 ; 68: 1030-1035
47. Munakata Y, Saito T, Matsuda K, et al. Detection of complement-fixing antiphospholipid antibodies in association with thrombosis. Thromb Haemost. 2000 ; 83: 728-731
48. Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Immunol. 1992 ; 10: 455-460
49. Schafer H, Mathey D, Hugo F, Bhakdi S. Deposition of the terminal C5b-9 complement complex in infracted areas of human myocardium. J Immunol. 1986 ; 137: 1945-1949
50. Kilgore KS, Schmid E, Shanley TP, et al. Sublytic concentrations of the membrane attack complex of complement induce interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol. 1997 ; 150: 2019-2031
51. Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood. 1986 ; 68: 875-880